Loading…

Outcomes with the Boston Type 1 Keratoprosthesis at Instituto de Microcirugía Ocular IMO

To report the outcomes on the Boston Type 1 Keratoprosthesis at our institution. Retrospective analysis case series. We analyzed 54 eyes of 53 patients who previously underwent Boston Type 1 Keratoprosthesis surgery at our institution from July 2006 to March 2011. Preoperative and postoperative para...

Full description

Saved in:
Bibliographic Details
Published in:Saudi journal of ophthalmology 2011-07, Vol.25 (3), p.281-284
Main Authors: Güell, Jose L., Arcos, Edilio, Gris, Oscar, Aristizabal, Diego, Pacheco, Miguel, Sanchez, Claudia L., Manero, Felicidad
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c459t-1904dbcfe285b48756fa56b24ffa668028fc047923bb97d797ad6241aa3d42c83
cites cdi_FETCH-LOGICAL-c459t-1904dbcfe285b48756fa56b24ffa668028fc047923bb97d797ad6241aa3d42c83
container_end_page 284
container_issue 3
container_start_page 281
container_title Saudi journal of ophthalmology
container_volume 25
creator Güell, Jose L.
Arcos, Edilio
Gris, Oscar
Aristizabal, Diego
Pacheco, Miguel
Sanchez, Claudia L.
Manero, Felicidad
description To report the outcomes on the Boston Type 1 Keratoprosthesis at our institution. Retrospective analysis case series. We analyzed 54 eyes of 53 patients who previously underwent Boston Type 1 Keratoprosthesis surgery at our institution from July 2006 to March 2011. Preoperative and postoperative parameters were collected and analyzed. Visual acuity and keratoprosthesis stability. Common preoperative diagnoses were penetrating keratoplasty failure in 49 eyes (90.7%), chronic keratitis in 2 eyes (3.7%), ocular cicatricial pemphigoid in 1 eye (1.85%), Stevens Johnson syndrome in 1 eye (1.85%) and corneal vascularization in 1 eye (1.85%). Additionally, 40 eyes (74%) had preoperative glaucoma, and an Ahmed valve was implanted in 55% of them. Preoperative BCVA ranged from 20/200 to light perception. At an average follow-up of 20.15 months ± 12.7 (range, 1–56), postoperative vision improved to ⩾20/200 in 18 eyes (33.3%) and ⩾20/50 in 4 eyes (7.4%). The graft retention was 96%. The Boston Type 1 keratoprosthesis is a valid option for high-risk patients. The design improvements in the Boston keratoprosthesis, as well as the daily implementation of the therapeutic methods, have notably diminished occurrence of the most serious complications, such as corneal necrosis and endophthalmitis. As such, glaucoma and its subsequent complications now stand as the most prevalent prognostic factor in the long term.
doi_str_mv 10.1016/j.sjopt.2011.04.010
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3729705</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1319453411000579</els_id><sourcerecordid>1426748189</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-1904dbcfe285b48756fa56b24ffa668028fc047923bb97d797ad6241aa3d42c83</originalsourceid><addsrcrecordid>eNp9kclOHDEQhn0ICkvyBJEiH3OZxlt7OSQSoBBGgOZCDjlZbnc141FPu2O7QTxUnoIXS8MQlFxyKqnqr7-WD6EPlFSUUHm8qfImjqVihNKKiIpQ8gYdUE7NQtRc7KPDnDeESM01f4v2GTeSGK4O0I_VVHzcQsb3oaxxWQM-jbnEAd88jIApvoTkShzTnFxDDhm7gpdDLqFMJeIW8HXwKfqQptvHXw6v_NS7hJfXq3dor3N9hvcv8Qh9P_96c3axuFp9W56dXC28qE1ZUENE2_gOmK4boVUtO1fLhomuc1JqwnTniVCG8aYxqlVGuVYyQZ3jrWBe8yP0Zec7Ts0WWg9DSa63Ywpblx5sdMH-WxnC2t7GO8sVM4rUs8GnF4MUf06Qi92G7KHv3QBxypYKJpXQVJtZynfS-eScE3SvYyixTyDsxj6DsE8gLBF2BjF3ffx7w9eePxRmweedAOY_3QVINvsAg4c2JPDFtjH8d8BvaWSfGQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1426748189</pqid></control><display><type>article</type><title>Outcomes with the Boston Type 1 Keratoprosthesis at Instituto de Microcirugía Ocular IMO</title><source>PubMed Central(OA)</source><source>ScienceDirect Journals</source><creator>Güell, Jose L. ; Arcos, Edilio ; Gris, Oscar ; Aristizabal, Diego ; Pacheco, Miguel ; Sanchez, Claudia L. ; Manero, Felicidad</creator><creatorcontrib>Güell, Jose L. ; Arcos, Edilio ; Gris, Oscar ; Aristizabal, Diego ; Pacheco, Miguel ; Sanchez, Claudia L. ; Manero, Felicidad</creatorcontrib><description>To report the outcomes on the Boston Type 1 Keratoprosthesis at our institution. Retrospective analysis case series. We analyzed 54 eyes of 53 patients who previously underwent Boston Type 1 Keratoprosthesis surgery at our institution from July 2006 to March 2011. Preoperative and postoperative parameters were collected and analyzed. Visual acuity and keratoprosthesis stability. Common preoperative diagnoses were penetrating keratoplasty failure in 49 eyes (90.7%), chronic keratitis in 2 eyes (3.7%), ocular cicatricial pemphigoid in 1 eye (1.85%), Stevens Johnson syndrome in 1 eye (1.85%) and corneal vascularization in 1 eye (1.85%). Additionally, 40 eyes (74%) had preoperative glaucoma, and an Ahmed valve was implanted in 55% of them. Preoperative BCVA ranged from 20/200 to light perception. At an average follow-up of 20.15 months ± 12.7 (range, 1–56), postoperative vision improved to ⩾20/200 in 18 eyes (33.3%) and ⩾20/50 in 4 eyes (7.4%). The graft retention was 96%. The Boston Type 1 keratoprosthesis is a valid option for high-risk patients. The design improvements in the Boston keratoprosthesis, as well as the daily implementation of the therapeutic methods, have notably diminished occurrence of the most serious complications, such as corneal necrosis and endophthalmitis. As such, glaucoma and its subsequent complications now stand as the most prevalent prognostic factor in the long term.</description><identifier>ISSN: 1319-4534</identifier><identifier>DOI: 10.1016/j.sjopt.2011.04.010</identifier><identifier>PMID: 23960937</identifier><language>eng</language><publisher>Saudi Arabia: Elsevier B.V</publisher><subject>Boston Type 1 Keratoprosthesis ; Corneal necrosis ; Instituto de Microcirugía Ocular IMO ; Ocular cicatricial pemphigoid ; Original ; Stevens Johnson syndrome ; Visual acuity</subject><ispartof>Saudi journal of ophthalmology, 2011-07, Vol.25 (3), p.281-284</ispartof><rights>2011</rights><rights>2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-1904dbcfe285b48756fa56b24ffa668028fc047923bb97d797ad6241aa3d42c83</citedby><cites>FETCH-LOGICAL-c459t-1904dbcfe285b48756fa56b24ffa668028fc047923bb97d797ad6241aa3d42c83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3729705/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1319453411000579$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3549,27924,27925,45780,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23960937$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Güell, Jose L.</creatorcontrib><creatorcontrib>Arcos, Edilio</creatorcontrib><creatorcontrib>Gris, Oscar</creatorcontrib><creatorcontrib>Aristizabal, Diego</creatorcontrib><creatorcontrib>Pacheco, Miguel</creatorcontrib><creatorcontrib>Sanchez, Claudia L.</creatorcontrib><creatorcontrib>Manero, Felicidad</creatorcontrib><title>Outcomes with the Boston Type 1 Keratoprosthesis at Instituto de Microcirugía Ocular IMO</title><title>Saudi journal of ophthalmology</title><addtitle>Saudi J Ophthalmol</addtitle><description>To report the outcomes on the Boston Type 1 Keratoprosthesis at our institution. Retrospective analysis case series. We analyzed 54 eyes of 53 patients who previously underwent Boston Type 1 Keratoprosthesis surgery at our institution from July 2006 to March 2011. Preoperative and postoperative parameters were collected and analyzed. Visual acuity and keratoprosthesis stability. Common preoperative diagnoses were penetrating keratoplasty failure in 49 eyes (90.7%), chronic keratitis in 2 eyes (3.7%), ocular cicatricial pemphigoid in 1 eye (1.85%), Stevens Johnson syndrome in 1 eye (1.85%) and corneal vascularization in 1 eye (1.85%). Additionally, 40 eyes (74%) had preoperative glaucoma, and an Ahmed valve was implanted in 55% of them. Preoperative BCVA ranged from 20/200 to light perception. At an average follow-up of 20.15 months ± 12.7 (range, 1–56), postoperative vision improved to ⩾20/200 in 18 eyes (33.3%) and ⩾20/50 in 4 eyes (7.4%). The graft retention was 96%. The Boston Type 1 keratoprosthesis is a valid option for high-risk patients. The design improvements in the Boston keratoprosthesis, as well as the daily implementation of the therapeutic methods, have notably diminished occurrence of the most serious complications, such as corneal necrosis and endophthalmitis. As such, glaucoma and its subsequent complications now stand as the most prevalent prognostic factor in the long term.</description><subject>Boston Type 1 Keratoprosthesis</subject><subject>Corneal necrosis</subject><subject>Instituto de Microcirugía Ocular IMO</subject><subject>Ocular cicatricial pemphigoid</subject><subject>Original</subject><subject>Stevens Johnson syndrome</subject><subject>Visual acuity</subject><issn>1319-4534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp9kclOHDEQhn0ICkvyBJEiH3OZxlt7OSQSoBBGgOZCDjlZbnc141FPu2O7QTxUnoIXS8MQlFxyKqnqr7-WD6EPlFSUUHm8qfImjqVihNKKiIpQ8gYdUE7NQtRc7KPDnDeESM01f4v2GTeSGK4O0I_VVHzcQsb3oaxxWQM-jbnEAd88jIApvoTkShzTnFxDDhm7gpdDLqFMJeIW8HXwKfqQptvHXw6v_NS7hJfXq3dor3N9hvcv8Qh9P_96c3axuFp9W56dXC28qE1ZUENE2_gOmK4boVUtO1fLhomuc1JqwnTniVCG8aYxqlVGuVYyQZ3jrWBe8yP0Zec7Ts0WWg9DSa63Ywpblx5sdMH-WxnC2t7GO8sVM4rUs8GnF4MUf06Qi92G7KHv3QBxypYKJpXQVJtZynfS-eScE3SvYyixTyDsxj6DsE8gLBF2BjF3ffx7w9eePxRmweedAOY_3QVINvsAg4c2JPDFtjH8d8BvaWSfGQ</recordid><startdate>20110701</startdate><enddate>20110701</enddate><creator>Güell, Jose L.</creator><creator>Arcos, Edilio</creator><creator>Gris, Oscar</creator><creator>Aristizabal, Diego</creator><creator>Pacheco, Miguel</creator><creator>Sanchez, Claudia L.</creator><creator>Manero, Felicidad</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20110701</creationdate><title>Outcomes with the Boston Type 1 Keratoprosthesis at Instituto de Microcirugía Ocular IMO</title><author>Güell, Jose L. ; Arcos, Edilio ; Gris, Oscar ; Aristizabal, Diego ; Pacheco, Miguel ; Sanchez, Claudia L. ; Manero, Felicidad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-1904dbcfe285b48756fa56b24ffa668028fc047923bb97d797ad6241aa3d42c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Boston Type 1 Keratoprosthesis</topic><topic>Corneal necrosis</topic><topic>Instituto de Microcirugía Ocular IMO</topic><topic>Ocular cicatricial pemphigoid</topic><topic>Original</topic><topic>Stevens Johnson syndrome</topic><topic>Visual acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Güell, Jose L.</creatorcontrib><creatorcontrib>Arcos, Edilio</creatorcontrib><creatorcontrib>Gris, Oscar</creatorcontrib><creatorcontrib>Aristizabal, Diego</creatorcontrib><creatorcontrib>Pacheco, Miguel</creatorcontrib><creatorcontrib>Sanchez, Claudia L.</creatorcontrib><creatorcontrib>Manero, Felicidad</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Saudi journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Güell, Jose L.</au><au>Arcos, Edilio</au><au>Gris, Oscar</au><au>Aristizabal, Diego</au><au>Pacheco, Miguel</au><au>Sanchez, Claudia L.</au><au>Manero, Felicidad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes with the Boston Type 1 Keratoprosthesis at Instituto de Microcirugía Ocular IMO</atitle><jtitle>Saudi journal of ophthalmology</jtitle><addtitle>Saudi J Ophthalmol</addtitle><date>2011-07-01</date><risdate>2011</risdate><volume>25</volume><issue>3</issue><spage>281</spage><epage>284</epage><pages>281-284</pages><issn>1319-4534</issn><abstract>To report the outcomes on the Boston Type 1 Keratoprosthesis at our institution. Retrospective analysis case series. We analyzed 54 eyes of 53 patients who previously underwent Boston Type 1 Keratoprosthesis surgery at our institution from July 2006 to March 2011. Preoperative and postoperative parameters were collected and analyzed. Visual acuity and keratoprosthesis stability. Common preoperative diagnoses were penetrating keratoplasty failure in 49 eyes (90.7%), chronic keratitis in 2 eyes (3.7%), ocular cicatricial pemphigoid in 1 eye (1.85%), Stevens Johnson syndrome in 1 eye (1.85%) and corneal vascularization in 1 eye (1.85%). Additionally, 40 eyes (74%) had preoperative glaucoma, and an Ahmed valve was implanted in 55% of them. Preoperative BCVA ranged from 20/200 to light perception. At an average follow-up of 20.15 months ± 12.7 (range, 1–56), postoperative vision improved to ⩾20/200 in 18 eyes (33.3%) and ⩾20/50 in 4 eyes (7.4%). The graft retention was 96%. The Boston Type 1 keratoprosthesis is a valid option for high-risk patients. The design improvements in the Boston keratoprosthesis, as well as the daily implementation of the therapeutic methods, have notably diminished occurrence of the most serious complications, such as corneal necrosis and endophthalmitis. As such, glaucoma and its subsequent complications now stand as the most prevalent prognostic factor in the long term.</abstract><cop>Saudi Arabia</cop><pub>Elsevier B.V</pub><pmid>23960937</pmid><doi>10.1016/j.sjopt.2011.04.010</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1319-4534
ispartof Saudi journal of ophthalmology, 2011-07, Vol.25 (3), p.281-284
issn 1319-4534
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3729705
source PubMed Central(OA); ScienceDirect Journals
subjects Boston Type 1 Keratoprosthesis
Corneal necrosis
Instituto de Microcirugía Ocular IMO
Ocular cicatricial pemphigoid
Original
Stevens Johnson syndrome
Visual acuity
title Outcomes with the Boston Type 1 Keratoprosthesis at Instituto de Microcirugía Ocular IMO
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T02%3A24%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20with%20the%20Boston%20Type%201%20Keratoprosthesis%20at%20Instituto%20de%20Microcirug%C3%ADa%20Ocular%20IMO&rft.jtitle=Saudi%20journal%20of%20ophthalmology&rft.au=G%C3%BCell,%20Jose%20L.&rft.date=2011-07-01&rft.volume=25&rft.issue=3&rft.spage=281&rft.epage=284&rft.pages=281-284&rft.issn=1319-4534&rft_id=info:doi/10.1016/j.sjopt.2011.04.010&rft_dat=%3Cproquest_pubme%3E1426748189%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c459t-1904dbcfe285b48756fa56b24ffa668028fc047923bb97d797ad6241aa3d42c83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1426748189&rft_id=info:pmid/23960937&rfr_iscdi=true